Published in Am J Physiol Lung Cell Mol Physiol on October 02, 2015
Trial of Imatinib for Hospitalized Adults With COVID-19 | NCT04394416
Absence of TNF-α enhances inflammatory response in the newborn lung undergoing mechanical ventilation. Am J Physiol Lung Cell Mol Physiol (2016) 0.77
Endothelial Cell Signaling and Ventilator-Induced Lung Injury (VILI): Molecular Mechanisms, Genomic Analyses & Therapeutic Targets. Am J Physiol Lung Cell Mol Physiol (2016) 0.75
Dysregulated Nox4 ubiquitination contributes to redox imbalance and age-related severity of acute lung injury. Am J Physiol Lung Cell Mol Physiol (2017) 0.75
The ARP 2/3 complex mediates endothelial barrier function and recovery. Pulm Circ (2017) 0.75
Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med (2000) 48.03
The acute respiratory distress syndrome. N Engl J Med (2000) 25.38
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med (2001) 24.51
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med (2006) 22.86
The pathophysiology and treatment of sepsis. N Engl J Med (2003) 21.67
Cytoskeletal regulation of pulmonary vascular permeability. J Appl Physiol (1985) (2001) 5.63
Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers. FASEB J (1995) 5.59
Ventilator-induced lung injury. N Engl J Med (2013) 5.40
IkappaB kinases phosphorylate NF-kappaB p65 subunit on serine 536 in the transactivation domain. J Biol Chem (1999) 5.16
Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest (2005) 4.74
Recent trends in acute lung injury mortality: 1996-2005. Crit Care Med (2009) 3.86
Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nat Med (2008) 3.64
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood (2007) 3.59
Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest (2004) 3.44
Clinical pharmacokinetics of imatinib. Clin Pharmacokinet (2005) 2.08
Reversal of vascular leak with imatinib. Am J Respir Crit Care Med (2013) 2.01
Ventilation-induced chemokine and cytokine release is associated with activation of nuclear factor-kappaB and is blocked by steroids. Am J Respir Crit Care Med (2001) 1.86
Effective treatment of edema and endothelial barrier dysfunction with imatinib. Circulation (2012) 1.70
Imatinib ameliorates neuroinflammation in a rat model of multiple sclerosis by enhancing blood-brain barrier integrity and by modulating the peripheral immune response. PLoS One (2013) 1.57
Re-evaluation of Evans Blue dye as a marker of albumin clearance in murine models of acute lung injury. Transl Res (2007) 1.47
Ventilation-induced neutrophil infiltration depends on c-Jun N-terminal kinase. Am J Respir Crit Care Med (2003) 1.41
Amelioration of diabetes by imatinib mesylate (Gleevec): role of beta-cell NF-kappaB activation and anti-apoptotic preconditioning. FASEB J (2006) 1.29
Role for nuclear factor-kappaB in augmented lung injury because of interaction between hyperoxia and high stretch ventilation. Transl Res (2009) 1.26
The kinase inhibitor imatinib mesylate inhibits TNF-{alpha} production in vitro and prevents TNF-dependent acute hepatic inflammation. Proc Natl Acad Sci U S A (2005) 1.23
Abl tyrosine kinase phosphorylates nonmuscle Myosin light chain kinase to regulate endothelial barrier function. Mol Biol Cell (2010) 1.23
Glutathione peroxidase 1 is regulated by the c-Abl and Arg tyrosine kinases. J Biol Chem (2003) 1.22
Catalase activity is regulated by c-Abl and Arg in the oxidative stress response. J Biol Chem (2003) 1.18
Imatinib mesylate and dermatology part 2: a review of the cutaneous side effects of imatinib mesylate. J Drugs Dermatol (2006) 1.17
Ventilation-induced activation of the mitogen-activated protein kinase pathway. Eur Respir J (2002) 1.17
Molecular mechanisms of lung cell activation induced by cyclic stretch. Crit Care Med (2003) 1.05
Endothelial cell myosin light chain kinase (MLCK) regulates TNFalpha-induced NFkappaB activity. J Cell Biochem (2005) 1.02
Abl kinases are required for vascular function, Tie2 expression, and angiopoietin-1-mediated survival. Proc Natl Acad Sci U S A (2013) 1.01
FTY720-induced human pulmonary endothelial barrier enhancement is mediated by c-Abl. Eur Respir J (2010) 0.97
Complete resolution of life-threatening bleomycin-induced pneumonitis after treatment with imatinib mesylate in a patient with Hodgkin's lymphoma: hope for severe chemotherapy-induced toxicity? J Clin Oncol (2011) 0.96
Comparative suppressive effects of tyrosine kinase inhibitors imatinib and nilotinib in models of autoimmune arthritis. Mod Rheumatol (2010) 0.90
Imatinib treatment inhibit IL-6, IL-8, NF-KB and AP-1 production and modulate intracellular calcium in CML patients. J Cell Physiol (2012) 0.88
Unexpected pleural effusions in 3 pediatric patients treated with STI-571. J Pediatr Hematol Oncol (2002) 0.88
NF-κB activation in myeloid cells mediates ventilator-induced lung injury. Respir Res (2013) 0.88
Improvement of ventilation-induced lung injury in a rodent model by inhibition of inhibitory κB kinase. J Trauma Acute Care Surg (2014) 0.87
Ventilator-induced injury augments interleukin-1beta production and neutrophil sequestration in lipopolysaccharide-treated lungs. Shock (2007) 0.87
Pleiotropic effects of interleukin-6 in a "two-hit" murine model of acute respiratory distress syndrome. Pulm Circ (2014) 0.85
Effects of dimethyl sulfoxide in cholesterol-containing lipid membranes: a comparative study of experiments in silico and with cells. PLoS One (2012) 0.85
Permeability of endothelial barrier: cell culture and in vivo models. Methods Mol Biol (2011) 0.84
Possible role of imatinib in clinical pulmonary veno-occlusive disease. Eur Respir J (2008) 0.83
Effect of tyrosine kinase inhibitors, imatinib and nilotinib, in murine lipopolysaccharide-induced acute lung injury during neutropenia recovery. Crit Care (2013) 0.83
Activations of mitogen-activated protein kinase and nuclear factor-kappaB by mechanical stretch result in ventilation-induced lung injury. Med Hypotheses (2006) 0.83
Differential and opposing effects of imatinib on LPS- and ventilator-induced lung injury. Am J Physiol Lung Cell Mol Physiol (2014) 0.82
Abl family kinases regulate endothelial barrier function in vitro and in mice. PLoS One (2013) 0.82
Protein kinase G increases antioxidant function in lung microvascular endothelial cells by inhibiting the c-Abl tyrosine kinase. Am J Physiol Cell Physiol (2014) 0.81
Metronidazole leads to enhanced uptake of imatinib in brain, liver and kidney without affecting its plasma pharmacokinetics in mice. J Pharm Pharmacol (2011) 0.80
Effects of Imatinib Mesylate (Gleevec) on human islet NF-kappaB activation and chemokine production in vitro. PLoS One (2011) 0.80
c-Abl-mediated tyrosine phosphorylation of the T-bet DNA-binding domain regulates CD4+ T-cell differentiation and allergic lung inflammation. Mol Cell Biol (2011) 0.79
Role of GADD45a in murine models of radiation- and bleomycin-induced lung injury. Am J Physiol Lung Cell Mol Physiol (2015) 0.75